Trials / Active Not Recruiting
Active Not RecruitingNCT03266055
Effects of Blueberry on Gut Microbiota and Metabolic Syndrome
Prebiotic Effects of Blueberry in Overweight/Obese Individuals: Potential Role of the Gut Microbiota in Alleviating the Metabolic Syndrome.
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Laval University · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
There is growing evidence that nutritional intervention with dietary polyphenols can positively modulate the gut microbiota to improve cardiometabolic health. Whether the beneficial effects of blueberries on obesity and the metabolic syndrome can be linked to their potential impact on the gut microbiota and intestinal integrity remains speculative at this time. Moreover, the mechanisms of action underlying health benefits associated to blueberry consumption are still unknown. The investigators are thus proposing to combine the study of metagenomics, transcriptomics and metabolomics to test whether a prebiotic activity of highbush blueberries can play a role in the prevention of obesity-linked metabolic syndrome in a clinical setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | 50 g of blueberry powder, taken daily for 8 weeks | Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters. |
| DIETARY_SUPPLEMENT | 50g of placebo blueberry powder, taken daily for 8 weeks | Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder). |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2019-01-14
- Completion
- 2025-12-01
- First posted
- 2017-08-29
- Last updated
- 2025-12-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03266055. Inclusion in this directory is not an endorsement.